Nuance Pharma to acquire Sino Health.

Nuance Pharma, a Shanghai-headquartered specialty care focused biopharma company, agreed to acquire Sino Health, a medical service provider. Financial terms were not disclosed. "This is another important milestone for Nuance in the implementation of our 'Dual Wheel' strategy. While bringing together global innovative assets, we continuously put our efforts in commercialization of products in high value therapeutic area's across China. The acquisition not only enriches our portfolio, through expansion into the emergency care, but also strengthens the sales network and supply chain capabilities and the Company's commercial footprint. The deal also materially improves our working capital and cash flow whilst generating multiple synergies on the commercialization of assets across China. Under the current market volatility, the transaction will ensure that Nuance is well-positioned for existing and future needs for commercialization," Mark Gavin Lotter, Nuance CEO.